Bolzon A

University of Padua

1
Publications in this database

PubMed name variants: Bolzon A. Uses the same surname-and-first-initial grouping as the researcher table; matches are not verified identities.

6
Career-wide h-index · OpenAlex
(122 citations, 27 total works)

Career-wide Research Topics · OpenAlex

Topic counts cover the OpenAlex author’s full publication record, across all conditions.

Hair Growth and Disorders (7)Dermatology and Skin Diseases (4)Nail Diseases and Treatments (4)Genetic and rare skin diseases. (4)melanin and skin pigmentation (3)

Erythromelalgia Publications

Osimertinib‑induced erythromelalgia: A case report.

Bolzon A, Alessia Guidotti A, Alaibac MAS
Experimental and therapeutic medicine •

The present study reports a case of osimertinib-induced erythromelalgia in a patient with metastatic lung adenocarcinoma. Osimertinib is an antineoplastic drug that irreversibly inhibits the epidermal growth factor receptor (EGFR) pathway by binding to the intracellular receptor tyrosine kinase site, thus preventing EGFR signal transduction. A 77-year-old female with a lung adenocarcinoma recurrence with secondary metastases was prescribed osimertinib therapy. The patient presented with painful erythema and warmth in the distal phalanges of all fingers on both hands, which worsened with heat and relieved with cold. Based on clinical data, erythromelalgia was diagnosed. Considering the age of onset, a primary erythromelalgia was ruled out. Further investigations excluded other secondary causes of erythromelalgia, therefore osimertinib was suspected as the cause. Although no cases of EGFR inhibitor-induced erythromelalgia have been reported, cutaneous adverse events induced by EGFR inhibitors have been documented. The present case may be the first evidence of osimertinib-induced erythromelalgia and may help clinicians to properly support patients who develop this EGFR inhibitor adverse event.